Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 1/20 | 0.36 |
| ▸ | POLRMT | O00411 | 1/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 5/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 4/20 | 0.33 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.32 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19344311 | 1.00 | STING1 (0.36) | STING1POLRMTPRMT5WDR77ACVRL1 | |
| SCHEMBL19344309 | 0.90 | PRMT5 (0.35) | STING1POLRMTPRMT5WDR77ACVRL1 | |
| SCHEMBL19344310 | 0.90 | PRMT5 (0.35) | STING1POLRMTPRMT5WDR77ACVRL1 | |
| SCHEMBL19344177 | 0.89 | PRMT5 (0.41) | STING1POLRMTPRMT5WDR77ACVRL1 | |
| SCHEMBL19344308 | 0.88 | POLRMT (0.34) | STING1POLRMTPRMT5WDR77 | |
| SCHEMBL22435122 | 0.88 | POLRMT (0.34) | STING1POLRMTPRMT5WDR77 | |
| SCHEMBL23584792 | 0.87 | DOT1L (0.36) | STING1POLRMTPRMT5WDR77DOT1L | |
| SCHEMBL19344307 | 0.87 | DOT1L (0.36) | STING1POLRMTPRMT5WDR77DOT1L | |
| SCHEMBL23584648 | 0.85 | STING1 (0.33) | STING1POLRMTDOT1L | |
| SCHEMBL19343942 | 0.84 | POLRMT (0.32) | STING1POLRMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200289539-A1 | NOVEL SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-09-17 | — | — | US | disclosed |
| WO-2017153186-A1 | SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200289539-A1 | NOVEL SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | STING1 1670/4885POLRMT 407/4885PRMT5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.